First identified in the central Chinese city of Wuhan in December 2019, the novel SARS-CoV-2 coronavirus has rapidly spread across the world, leading to the most serious pandemic in recent history.
Inria, ANSSI, Capgemini, Dassault Systèmes, Inserm, Lunabee Studio, Orange, Santé Publique France and Withings create the StopCovid project team in order to structure and strengthen their contribution to the government project to set up a mobile contact tracing application (StopCovid). The purpose of this project is to provide the French health authorities with a complementary digital tool to help manage the sanitary emergency against Covid-19.
Inserm has played a leading role in the French and international research spheres, rallying its many experts in subjects related to fundamental research, therapeutic research, and modelling. Participating also in France’s solidarity effort, the Institute has taken action to distribute tens of thousands of masks, gloves, gowns, shoe covers and reagents to medical teams working in the nation’s hospitals.
For a deeper insight into the social and epidemiological challenges posed by the exceptional prevention measures taken in response to the COVID-19 pandemic – particularly confinement – a multidisciplinary group of researchers has joined forces with Inserm and the Public Health Agency to launch a survey of around 200,000 participants from five major French cohorts.
In order to obtain accurate mortality figures on the COVID-19 pandemic, the data provided by the various entities authorized to issue death certificates – health care establishments, community doctors, emergency medical service (SAMU), and care homes for the elderly – need to be collected quickly. The widespread deployment of electronic death certification made possible by Inserm through its CertDc application should enable rapid acquisition of the figures needed, in...
The teams of the Infectious and Tropical Diseases Hospital Bichat AP-HP and the University Hospital of Bordeaux, in collaboration with researchers from University of Paris, Inserm IAME UMRS-1137 (University of Paris / INSERM / University Sorbonne Paris Nord), the Institut Pasteur, the Hospices Civils de Lyon, CNRS - UMR 5308, Ecole Normale Supérieure de Lyon and University Claude Bernard Lyon, published a study based on the monitoring of the...
The AP-HP, the Federation of Diabetological Hospital Service and the AP-HP Connected Health Responsibility Centre offer this week to diabetic patients confined at home during the Covid-19 outbreak, a national programme of information, prevention and support for their health.
Inserm has joined forces with telecommunications company Orange to study the impact of confinement on population mobility and explore how using aggregated cellphone data could improve COVID-19 pandemic predictions.
At a time when the Sars-CoV-2 epidemic is continuing to spread, France’s Alliance for Life Sciences and Health (Aviesan) is mobilizing to accelerate research into the virus and COVID-19 disease through REACTing – a consortium coordinated by Inserm. The Scientific Advisory Board of REACTing has selected 20 scientific initiatives covering diverse fields, from mathematical modelling to disease prevention and treatment.
Egypt, Algeria and Republic of South Africa are the African countries most at risk for coronavirus COVID-19 importation in the continent, due to high air traffic with the contaminated Chinese provinces. But these countries are also among the best equipped on the continent to quickly detect and deal with new cases. In other African countries, the risk of importation is lower, but health organization deficiencies raise concerns about rapid...
An organic compound produced by the gut flora – the metabolite 4-Cresol – is considered to have protective effects against both type 1 and 2 diabetes, notably by stimulating the growth of the insulin-producing pancreatic beta cells. This is according to a new study led by Inserm researcher Dominique Gauguier. These findings open up new therapeutic avenues which could improve the situation of millions of patients.
